Vertex Pharmaceuticals Inc., headquartered in Boston, Massachusetts, is a leading global biotechnology company dedicated to scientific innovation and the development of transformative medicines for individuals with serious and life-threatening diseases. Founded in 1989 in Cambridge, Massachusetts, Vertex has made significant strides in the field of cystic fibrosis (CF), being the first to discover and develop therapies that address the underlying genetic causes of this rare and debilitating condition. The company's commitment to advancing healthcare is evident in its robust pipeline, which includes over a dozen ongoing research programs targeting various serious diseases beyond CF.
With a workforce of approximately 2,500 employees spread across the United States, Europe, Canada, Australia, and Latin America, Vertex places a strong emphasis on research and development, with nearly two-thirds of its staff dedicated to this critical area. The company’s innovative approach leverages cutting-edge technologies and methodologies, including gene editing and personalized medicine, to create effective treatments that improve patient outcomes.
Vertex Pharmaceuticals has garnered numerous accolades, consistently being recognized as one of the best places to work by prestigious publications such as Science Magazine and The Boston Globe. Its research and therapeutic advancements have also been honored with awards like the Robert J. Beall Therapeutics Development Award and the French Prix Galien, underscoring its impact on the biotechnology industry. As Vertex continues to push the boundaries of scientific discovery, it remains committed to its mission of providing hope and improved quality of life for patients facing serious health challenges.
|
|
|
5,001-10,000 employees
View all Vertex Pharmaceuticals employees
|
|
biotechnology
|
|
Vertex Pharmaceuticals Inc.,Boston,MA,United States
|
|
1989
|
|
Cystic Fibrosis, Alpha-1 Antitrypsin Deficiency (Aatd), Apol1-Mediated Kidney Diseases, Sickle Cell Disease, Beta Thalassemia, Duchenne Muscular Dystrophy, Type 1 Diabetes Mellitus
|
Addison Rubenstein is the CEO of Vertex Pharmaceuticals. To contact Addison Rubenstein email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.